SynthesisEuropean journal of clinical pharmacology2026
Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary G-CSF prophylaxis in sacituzumab govitecan-treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer.European journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials have demonstrated favorable outcomes with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). However, significant differences between trial settings and routine clinical practice raise concerns about the real-world prognosis of patients with mTNBC. To address this gap, we conducted the first comprehensive single-arm meta-analysis integrating clinical trials and real-world studies (RWSs) to evaluate clinical outcomes and treatment experiences in mTNBC patients receiving SG.
methodsRelevant studies were searched systematically in seven databases as of November 2024. Clinical trials and RWS of patients receiving SG for mTNBC were included. The primary outcomes of this study were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs).
resultsThe meta-analysis included 1 randomized controlled trial (RCT), 4 single-arm trials and 9 RWSs with a total of 1387 patients. Direct meta-analysis results showed that the overall random-effects pooled prevalence of OS, PFS, and ORR were 11.26 months (95% CI: 9.68-12.84), 4.88 months (95% CI: 4.34-5.41) and 32% (95% CI: 29%-35%) respectively. Clinical study group demonstrated outcomes of OS: 12.93 months (95% CI: 11.51-14.35), PFS: 5.67 months (95% CI: 5.10-6.25), and ORR: 34% (95% CI: 30%-38%), in contrast to RWS group, with OS: 9.7 months (95% CI: 8.63-10.77), PFS: 4.32 months (95% CI: 3.86-4.79), and ORR: 30% (95% CI: 25%-34%). The most common treatment-related adverse events from SG were neutropenia, nausea, anemia and fatigue.
conclusionThis single-arm analysis aims to compile scientific evidence on SG to provide valuable insights into the management of patients with mTNBC. Further randomized trials to analyze its effectiveness and safety are needed. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42024553989.
Indexed as
Identifiers
41546725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.